Moreover, future studies on the relevance of MGMT promotor methylation will need to discuss whether patients with pleomorphic xanthastrocytomas should be excluded from the larger group of gliomas WHO grade II given that such patients may have distinct outcome compared to diffuse glioma1, and the relevance of MGMT promotor status is highly unclear in this peculiar cohort23. The gene discussed is MGMT; the disease is central nervous system cancer.